Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy

Neelima Vidula1 and Hope S. Rugo2

Triple-negative breast cancer (TNBC) has a poor prognosis with limited treatment options. Genomic analysis of TNBCs offers the opportunity to decode TNBC into biologically relevant subtypes with unique molecular targets. With further research, these findings may be translated into effective targeted therapeutic options. Clin Cancer Res; 21(7); 1–3. ©2014 AACR.

See related article by Burstein et al. p. 1688

In this issue of Clinical Cancer Research, Burstein and colleagues (1) describe the findings of a genomic analysis of triple-negative breast cancer (TNBC). TNBC has been conventionally described as breast cancer that does not express the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), although recent studies suggest that TNBC is actually quite heterogeneous (2). Using DNA and RNA profiling of 198 TNBC tumors, Burstein and colleagues (1) describe four subtypes of TNBCs with prognostic significance, identified by specific gene amplifications, termed luminal-androgen receptor (LAR), mesenchymal (MES), basal-like immune-suppressed (BLIS), and basal-like immune-activated (BLIA) subtypes. The authors conclude that TNBC can be categorized as four subtypes based on discrete molecular markers, which can then be used to identify potentially effective targeted agents.

How do we apply these data to the clinic? TNBC is a difficult to treat subtype of breast cancer, with a high propensity for systemic metastases and poor survival. Chemotherapy resistance is common, and, to date, there are no effective alternative treatments. In the clinic, it is clear that TNBC represents a heterogeneous subset of cancers, with markedly different natural histories and response to therapy, and that additional tumor specific information is critical to finding effective therapies. Lehmann and colleagues (2) previously described six subtypes of TNBC and identified an indolent, AR-expressing subset. Burstein and colleagues describe four subtypes, with some overlap, and were unable to reproduce Lehmann and colleagues’ subtype definitions. The classification by Burstein and colleagues also differs from Prat and Perou’s (3) categorization defining claudin low, luminal A, luminal B, HER2-positive, and basal-like subtypes, and from the grouping of Curtis and colleagues (4) using copy-number aberrations. These differences, which may be due in part to methodology and datasets, complicate ultimate definitions but may not be clinically relevant, as the identification of actionable targets is most important to the clinic, providing a path for directed clinical research. Indeed, these studies expand the paradigm of TNBC from a disease that has been defined by the absence of hormone or HER2 receptor expression into a heterogeneous cancer defined by the presence of specific gene products (Fig. 1).

Data from these efforts have already been tested in laboratory models and clinical trials, with intriguing results. Lehmann and colleagues noted a high frequency of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutations in AR-differentiated TNBCs, and found that combining phosphoinositide 3-kinase inhibitors and AR antagonists in this subtype had an additive inhibitory effect, suggesting a role for combined therapy with further differentiation of AR-positive TNBC (5). A study from the translational Breast Cancer Research Consortium tested tumor samples from patients with TNBC and found that 12% expressed AR (6). Treatment with the AR antagonist bicalutamide resulted in a 19% 6-month clinical benefit rate, which is impressive for a TNBC subtype. Ongoing studies are testing alternative AR inhibitors in AR-positive TNBC. Therapies already exist that target additional gene products identified by Burstein and colleagues, including IGFI and prostaglandin inhibitors for MES tumors, pembrolizumab (anti-programmed cell death 1 antibody) and VTCN1 antibodies for BLIS tumors, and STAT inhibitors and ipilimumab (anti–CTLA-4 antibody) for BLIA tumors. Clinical trials focusing on these targets are the next step.

This work adds to efforts translating molecular markers into precise cancer therapies. While Burstein and colleagues (1) have identified several gene products for different TNBC subtypes, there is significant genetic diversity within these subtypes. A prior study showed that TNBC has a high mutation rate, leading to the
acquisition of various point mutations with resulting clonal diversity (7). Therefore, several genomic alterations may be responsible for a tumor's growth, increasing the difficulty of transforming a molecular marker into an effective therapy. A single mutation may exist in only a portion of the tumor, and this may change under the pressure of treatment. This heterogeneity within a tumor makes combination therapy not only appealing but also highly challenging.

Molecular evolution occurs as cancer progresses, so resistance may develop to targets identified on a primary tumor, or new mutations may appear in a metastatic lesion. Essentially, all of the biopsy specimens in the study by Burstein and colleagues were from primary tumors; hence, it is possible that the molecular targets described may vary or have additional complexity in the metastatic setting. Arnedos and colleagues (8) performed whole exome sequencing of 93 pairs of metastatic breast cancer biopsy and blood samples and noted that mutations in estrogen receptor 1 (ESR1), tuberous sclerosis 1/2 (TSC1/2), and DOT1-like histone H3K79 methyltransferase (DOT1L) occurred in 5% of metastatic specimens, but were seen in less than 1% of early tumors. The evaluation of matched primary and metastatic tumor biopsies may help us to understand these potential confounding factors and further define targets within TNBC. Blackwell and colleagues (9) performed exome sequencing of metastatic and primary tumor samples from 38 patients with metastatic TNBC and found marked genetic heterogeneity, with increased mutations in metastatic tumors. These data, and those from other researchers, suggest that genetic composition evolves over time and with exposure to treatment. Clearly, further research is needed to define targets for both primary and metastatic TNBCs.

Several ongoing trials may further elucidate the activity of targeted therapies chosen based on specific tumor mutations in a variety of malignancies. The NCI's Molecular Analysis for Therapy Choice Program (MATCH) is a multiamr phase II trial for patients with advanced cancer (10). Patients will undergo tumor biopsies with DNA sequencing. Those whose tumors have targetable mutations will be assigned to treatment with the appropriate targeted agent; the primary endpoint is tumor response across tumor types. The ongoing French SAFIR02 trial has a similar design, including both lung and breast cancers.

Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer (AURORA) is a program enrolling 1,300 patients with metastatic breast cancer in Europe (11). Patients' primary tumors, metastatic lesions, and peripheral blood undergo DNA sequencing to determine individual cancer genomic profiles.

This study, together with previous work, illustrates that TNBC is more complex than a subset of breast cancer not expressing ER, PR, and HER2. However, this study also highlights the extent of entropy in the genomic landscape of breast cancer. With ongoing research efforts, we will one day be able to translate these molecular targets into effective personalized therapies for TNBC.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: N. Vidula, H.S. Rugo
Development of methodology: N. Vidula
References


